Status | Study |
Active, not recruiting |
Study Name: Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert Condition: Posterior Uveitis Intermediate Uveitis Panuveitis Date: 2012-09-24 Interventions: Drug: FAI insert Drug: Sham injection |
Completed |
Study Name: Effect of Spironolactone in Treating Chronic Non-resolutive Central Serous Chorioretinitis Condition: Central Serous Chorioretinitis Date: 2012-02-14 Interventions: Drug: Spironolactone 25mg tabl |
Recruiting |
Study Name: Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis , Condition: Non-infectious Intermediate Uveitis Non-infectious Posterior Uveitis Date: 2012-02-01 Interventions: Drug: LFG316 LFG316 administer |
Recruiting |
Study Name: Intravitreal Sirolimus as Therapeutic Approach to Uveitis Condition: Uveitis Intermediate Uveitis Posterior Uveitis Date: 2011-01-20 Interventions: Drug: Intravitreal injection 440mcg |
Withdrawn |
Study Name: Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD Condition: Choroidal Neovascularization Myopia Punctate Inner Choroid Date: 2010-10-29 Interventions: Drug: Bevacizumab (Avastin; Genentech, Inc.) |
Completed |
Study Name: Myfortic for the Treatment of Non-infectious Intermediate Uveitis Condition: Uveitis, Intermediate Date: 2010-03-23 Interventions: Drug: Myfortic Myfortic 360 mg |
Recruiting |
Study Name: Sirolimus as Therapeutic Approach to Uveitis Condition: Uveitis Intermediate Uveitis Posterior Uveitis Date: 2009-04-30 Interventions: Drug: Sirolimus (rapamycin) Wi |
Completed |
Study Name: Intravitreal Bevacizumab in Recalcitrant Inflammatory Ocular Neovascularization Condition: Neovascularization Tuberculosis Multifocal Serpiginous Date: 2008-03-25 |
Completed |
Study Name: Retisert and Cataract Surgery in Patients With Severe Uveitis Condition: Intermediate Uveitis Posterior Uveitis Date: 2007-12-10 Interventions: Device: Retisert (fluocinolone acetonide implant) Patients with intermediate, posterior or pan-uveitis u |
Completed |
Study Name: Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy Condition: Coats' Disease Idiopathic Retinal Telangiectasia Retinal A Date: 2007-05-04 Interventions: Drug: ranibizumab injection (0.5 mg) ranibizumab 10mg mg/ml. , 0.3ml/vial, 0.05 ml./injection intravitre |